IPF affects the tissue surrounding the air sacs, or alveoli, in the lungs. This condition develops when lung tissue becomes ...

Pulmonary fibrosis in patients with COVID-19 tends to resolve, while idiopathic pulmonary fibrosis always progresses.

Several years ago, my dad was diagnosed with pulmonary fibrosis. The news was a shock. At 84 years old, Daddy had been ...

Idiopathic Pulmonary Fibrosis (IPF) is a chronic interstitial lung disease characterized by progressive scarring of lung tissue, which impairs oxygen exchange and leads to breathing difficulties.

Panelists discuss the potential role of emerging treatments in the progressive pulmonary fibrosis (PPF) landscape if approved ...

Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it.

What we found in this study were the key immune elements (cells and genes) that may explain resolution versus progression of pulmonary fibrosis." IPF affects the tissue surrounding the air sacs ...

The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

Researchers reveal how targeting HIF2 could transform the treatment of idiopathic pulmonary fibrosis (IPF), offering hope for ...